​

Funding Round

Series C - Cagent Vascular

Series C - Cagent Vascular

Investment Firm

Overview

Cagent Vascular develops a serration technology for improving the treatment of cardiovascular disease.

Announced Date

Feb 20, 2024

Closed on Date

Feb 20, 2024

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

U.S. Venture Partners

U.S. Venture Partners

U.S. Venture Partners is a early_stage_venture and late_stage_venture and venture firm.

Participant Investors

3

Investor Name
Participant InvestorBlue Ridge Medical
Participant InvestorSectoral Asset Management
Participant InvestorU.S. Venture Partners

Round Details and Background

Cagent Vascular raised $30000000 on 2024-02-20 in Series C

Cagent Vascular develops a serration technology for improving the treatment of cardiovascular disease.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jul 12, 2018
Series B - Cagent Vascular
3-11.9M
Jun 23, 2021
Venture Round - Cagent Vascular
-9.5M
Feb 20, 2024
Series C - Cagent Vascular
3-30.0M
Jun 22, 2016
Seed Round - Cagent Vascular
1-500.0K

Recent Activity

There is no recent news or activity for this profile.